{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:48:08Z","timestamp":1778611688562,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008141","name":"Inge og J\u00f8rgen Larsens Mindelegat","doi-asserted-by":"publisher","award":["10537-006\/41"],"award-info":[{"award-number":["10537-006\/41"]}],"id":[{"id":"10.13039\/501100008141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018732","name":"Vissing Fonden","doi-asserted-by":"publisher","award":["525902"],"award-info":[{"award-number":["525902"]}],"id":[{"id":"10.13039\/100018732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R325-A18625"],"award-info":[{"award-number":["R325-A18625"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lymph node (LN) metastasis after neoadjuvant chemotherapy (NACT) generally warrants axillary lymph node dissection, which opposes guidelines of upfront surgery in many cases. We investigated the risk of having additional metastases in the axilla when the LNs removed by targeted axillary dissection (TAD) harbored metastases after NACT. We aimed to identify subgroups suitable for de-escalated axillary treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This register-based study used data from the Danish Breast Cancer Cooperative Group database. Data were analyzed with logistic regression models. The primary outcome was the metastatic burden in non-TAD LNs in patients with positive TAD LNs after NACT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 383 patients, &lt;\u200966.6% positive TAD LNs (adjusted odds ratio [OR] 0.34, 95% confidence interval [CI] 0.17\u20130.62), only isolated tumor cells (ITCs) [OR 0.11, 95% CI\u2009&lt;\u20090.01\u20130.82], and breast pathological complete response (pCR) [OR 0.07, 95% CI\u2009&lt;\u20090.01\u20130.56] were associated with a low risk of having more than three positive non-TAD LNs. In 315 patients with fewer than three positive non-TAD LNs, the proportion of positive TAD LNs (OR 0.45, 95% CI 0.27\u20130.76 for 33.3\u201366.6% vs. &gt;\u200966.6%), size of the TAD LN metastasis (OR 0.14, 95% CI 0.04\u20130.54 for ITC vs. macrometastasis), tumor size at diagnosis (OR 0.30, 95% CI 0.15\u20130.64 for 20\u201349\u00a0mm vs. \u2265\u200950\u00a0mm) and breast pCR (OR 0.38, 95% CI 0.15\u20130.96) were associated with residual LN metastases in the axilla.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Breast pCR or ITC only in TAD LNs can, with reasonable certainty, preclude more than three positive non-TAD LNs. Additionally, patients with only ITCs in the TAD LN had a low risk of having any non-TAD LN metastases after NACT. De-escalated axillary treatment may be considered in both subgroups.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15354-1","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T21:01:24Z","timestamp":1714856484000},"page":"5157-5167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study"],"prefix":"10.1245","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7659-7825","authenticated-orcid":false,"given":"Frederikke","family":"Munck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maj-Britt","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Vejborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria K.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja V.","family":"Maraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels T.","family":"Kroman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tove H. F.","family":"Tvedskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"3","key":"15354_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ultrasmedbio.2018.10.026","volume":"45","author":"WH Kim","year":"2019","unstructured":"Kim WH, Kim HJ, Park HY, et al. Axillary pathologic complete response to neoadjuvant chemotherapy in clinically node-positive breast cancer patients: a predictive model integrating the imaging characteristics of ultrasound restaging with known clinicopathologic characteristics. Ultrasound Med Biol. 2019;45(3):702\u20139. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2018.10.026.","journal-title":"Ultrasound Med Biol"},{"issue":"6","key":"15354_CR2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/tbj.13085","volume":"24","author":"G Vugts","year":"2018","unstructured":"Vugts G, Van den Heuvel F, Maaskant-Braat AJG, et al. Predicting breast and axillary response after neoadjuvant treatment for breast cancer: the role of histology vs receptor status. Breast J. 2018;24(6):894\u2013901. https:\/\/doi.org\/10.1111\/tbj.13085.","journal-title":"Breast J"},{"issue":"1","key":"15354_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1148\/radiol.2019190014","volume":"293","author":"R Kim","year":"2019","unstructured":"Kim R, Chang JM, Lee HB, et al. Predicting axillary response to neoadjuvant chemotherapy: breast MRI and US in patients with node-positive breast cancer. Radiology. 2019;293(1):49\u201357. https:\/\/doi.org\/10.1148\/radiol.2019190014.","journal-title":"Radiology"},{"issue":"5","key":"15354_CR4","doi-asserted-by":"publisher","first-page":"E553","DOI":"10.1097\/SLA.0000000000004572","volume":"276","author":"S Kuemmel","year":"2022","unstructured":"Kuemmel S, Heil J, Rueland A, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg. 2022;276(5):E553\u201362. https:\/\/doi.org\/10.1097\/SLA.0000000000004572.","journal-title":"Ann Surg"},{"issue":"7","key":"15354_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers13071565","volume":"13","author":"M Banys-paluchowski","year":"2021","unstructured":"Banys-paluchowski M, Gasparri ML, de Boniface J, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers (Basel). 2021;13(7):1565. https:\/\/doi.org\/10.3390\/cancers13071565.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"15354_CR6","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15354_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","volume":"157","author":"JM Simons","year":"2022","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC, van Diest PJ, Jager A, van Klaveren D, Kam BLR, Lobbes MBI, de Boer M, Verhoef C, Sars PRA, Heijmans HJ, van Haaren ERM, Vles WJ, Contant CME, Menke-Pluijmers MBE, Smit LHM, Kelder W, Boskamp M, Koppert LB, Ernest J, Marjolein S. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. JAMA Surg. 2022;157(11):991\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2022.3907.","journal-title":"JAMA Surg"},{"issue":"3","key":"15354_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201363. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol"},{"issue":"14","key":"15354_CR9","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA"},{"issue":"7","key":"15354_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"15354_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jso.25989","volume":"122","author":"M Cheng","year":"2020","unstructured":"Cheng M, Zhuang X, Zhang L, et al. A nomogram to predict non-sentinel lymph node metastasis in patients with initial cN+ breast cancer that downstages to cN0 after neoadjuvant chemotherapy. J Surg Oncol. 2020;122(3):373\u201381. https:\/\/doi.org\/10.1002\/jso.25989.","journal-title":"J Surg Oncol"},{"issue":"6","key":"15354_CR12","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"TA Moo","year":"2018","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25(6):1488\u201394. https:\/\/doi.org\/10.1245\/s10434-018-6429-2.","journal-title":"Ann Surg Oncol"},{"key":"15354_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.radonc.2021.08.013","volume":"163","author":"MC Leonardi","year":"2021","unstructured":"Leonardi MC, Arrobbio C, Gandini S, et al. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. Radiother Oncol. 2021;163:128\u201335. https:\/\/doi.org\/10.1016\/j.radonc.2021.08.013.","journal-title":"Radiother Oncol"},{"issue":"12","key":"15354_CR14","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1245\/s10434-022-12064-4","volume":"29","author":"SB Sanders","year":"2022","unstructured":"Sanders SB, Hoskin TL, Stafford AP, Boughey JC. Factors influencing non-sentinel lymph node involvement in patients with positive sentinel lymph node(s) after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2022;29(12):7769\u201378. https:\/\/doi.org\/10.1245\/s10434-022-12064-4.","journal-title":"Ann Surg Oncol"},{"issue":"33","key":"15354_CR15","doi-asserted-by":"publisher","first-page":"13820","DOI":"10.1073\/pnas.0905718106","volume":"106","author":"CJ Creighton","year":"2009","unstructured":"Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106(33):13820\u20135. https:\/\/doi.org\/10.1073\/pnas.0905718106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"15354_CR16","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Ann Oncol"},{"issue":"1","key":"15354_CR17","first-page":"14","volume":"1016","author":"Danish Breast Cancer Group","year":"2016","unstructured":"Danish Breast Cancer Group. Neoadjuverende kemoterapi ved brystkr\u00e6ft mhp. down-sizing og down-staging. DMCG Klin retningslinjer. 2016;1016(1):14.","journal-title":"DMCG Klin retningslinjer"},{"issue":"10","key":"15354_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/bjs.4725","volume":"91","author":"G Cserni","year":"2004","unstructured":"Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91(10):1245\u201352. https:\/\/doi.org\/10.1002\/bjs.4725.","journal-title":"Br J Surg"},{"issue":"22","key":"15354_CR19","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1093\/jnci\/djn343","volume":"100","author":"CHM Van Deurzen","year":"2008","unstructured":"Van Deurzen CHM, De Boer M, Monninkhof EM, et al. Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst. 2008;100(22):1574\u201380. https:\/\/doi.org\/10.1093\/jnci\/djn343.","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"15354_CR20","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline. J Clin Oncol. 2021;39(27):3056\u201382. https:\/\/doi.org\/10.1200\/JCO.21.00934.","journal-title":"J Clin Oncol"},{"issue":"18","key":"15354_CR21","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/jama.2009.1568","volume":"302","author":"R G\u00e4rtner","year":"2009","unstructured":"G\u00e4rtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302(18):1985\u201392. https:\/\/doi.org\/10.1001\/jama.2009.1568.","journal-title":"JAMA"},{"issue":"6","key":"15354_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.breast.2010.05.015","volume":"19","author":"R G\u00e4rtner","year":"2010","unstructured":"G\u00e4rtner R, Jensen MB, Kronborg L, Ewertz M, Kehlet H, Kroman N. Self-reported arm-lymphedema and functional impairment after breast cancer treatment: a nationwide study of prevalence and associated factors. Breast. 2010;19(6):506\u201315. https:\/\/doi.org\/10.1016\/j.breast.2010.05.015.","journal-title":"Breast"},{"key":"15354_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2147\/CLEP.S99457","volume":"8","author":"P Christiansen","year":"2016","unstructured":"Christiansen P, Ejlertsen B, Jensen M, Mouridsen H. Danish breast cancer cooperative group. Clin Epidemiol. 2016;8:445.","journal-title":"Clin Epidemiol"},{"issue":"20","key":"15354_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"15354_CR25","doi-asserted-by":"publisher","DOI":"10.32388\/b30ldk","volume-title":"AJCC cancer staging manual","author":"GN Hortobagyi","year":"2020","unstructured":"Hortobagyi GN, Connolly JL, Orsi CJD, et al. AJCC cancer staging manual. 8th edn. London: Qeios; 2020. https:\/\/doi.org\/10.32388\/b30ldk.","edition":"8"},{"key":"15354_CR26","unstructured":"Danish Breast Cancer Group. Systemisk behandling af brystkr\u00e6ft\u2014II. DMCG Klin retningslinjer. 2022;1(4):1\u201328. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/brystcancer\/. Accessed 29 Apr 2024."},{"key":"15354_CR27","unstructured":"Danish Breast Cancer Group. Medicinsk behandling. DMCG Klin Retningslinjer. 2019:1\u201337."},{"key":"15354_CR28","unstructured":"Danish Breast Cancer Group. Postoperativ str\u00e5lebehandling af brystkr\u00e6ft. DMCG Klin Retningslinjer. 2023;3:1\u201358. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/brystcancer\/. Accessed 29 Apr 2024."},{"key":"15354_CR29","unstructured":"Danish Breast Cancer Group. Neoadjuverende kemoterapi ved brystkr\u00e6ft. DMCG Klin Retningslinjer. 2021;1:1\u201337. https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/brystcancer\/. Accessed 29 Apr 2024."},{"issue":"1","key":"15354_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","volume":"193","author":"AA van Loevezijn","year":"2022","unstructured":"van Loevezijn AA, van der Noordaa MEM, Stokkel MPM, et al. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol. Breast Cancer Res Treat. 2022;193(1):37\u201348. https:\/\/doi.org\/10.1007\/s10549-022-06545-z.","journal-title":"Breast Cancer Res Treat."},{"key":"15354_CR31","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. Available at: https:\/\/www.r-project.org\/."},{"key":"15354_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1042394","volume":"13","author":"W Shi","year":"2022","unstructured":"Shi W, Huang X, Wang Y, et al. A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer. Front Endocrinol (Lausanne). 2022;13:1042394. https:\/\/doi.org\/10.3389\/fendo.2022.1042394.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"15354_CR33","doi-asserted-by":"publisher","first-page":"E89","DOI":"10.1503\/CJS.012920","volume":"65","author":"F Ladak","year":"2022","unstructured":"Ladak F, Chua N, Lesniak D, et al. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer. Can J Surg. 2022;65(1):E89\u201396. https:\/\/doi.org\/10.1503\/CJS.012920.","journal-title":"Can J Surg"},{"issue":"5","key":"15354_CR34","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1245\/s10434-018-6345-5","volume":"25","author":"O Kantor","year":"2018","unstructured":"Kantor O, Sipsy LMN, Yao K, James TA. A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2018;25(5):1304\u201311. https:\/\/doi.org\/10.1245\/s10434-018-6345-5.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"15354_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00595-019-01858-x","volume":"50","author":"N Iwamoto","year":"2020","unstructured":"Iwamoto N, Aruga T, Horiguchi S, et al. Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy. Surg Today. 2020;50(2):178\u201384. https:\/\/doi.org\/10.1007\/s00595-019-01858-x.","journal-title":"Surg Today"},{"issue":"43","key":"15354_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000001720","volume":"94","author":"JY Kim","year":"2015","unstructured":"Kim JY, Park HS, Kim S, Ryu J, Park S, Kim SI. Prognostic nomogram for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Med (United States). 2015;94(43):1\u20139. https:\/\/doi.org\/10.1097\/MD.0000000000001720.","journal-title":"Med (United States)"},{"issue":"10","key":"15354_CR37","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ijc.27499","volume":"131","author":"TF Tvedskov","year":"2012","unstructured":"Tvedskov TF, Jensen MB, Lisse IM, Ejlertsen B, Balslev E, Kroman N. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node. Int J Cancer. 2012;131(10):2367\u201375. https:\/\/doi.org\/10.1002\/ijc.27499.","journal-title":"Int J Cancer"},{"issue":"6","key":"15354_CR38","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546\u201353. https:\/\/doi.org\/10.1056\/NEJMoa012782.","journal-title":"N Engl J Med"},{"issue":"3","key":"15354_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00000658-199409000-00015","volume":"220","author":"AE Giuliano","year":"1994","unstructured":"Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391\u2013401. https:\/\/doi.org\/10.1097\/00000658-199409000-00015.","journal-title":"Ann Surg"},{"issue":"8","key":"15354_CR40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","volume":"158","author":"S Kuemmel","year":"2023","unstructured":"Kuemmel S, Heil J, Bruzas S, et al. Safety of Targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158(8):807\u201315. https:\/\/doi.org\/10.1001\/jamasurg.2023.1772.","journal-title":"JAMA Surg"},{"issue":"6","key":"15354_CR41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/ans.15173","volume":"89","author":"G Tapia","year":"2019","unstructured":"Tapia G, Ying V, Di Re A, Stellin A, Cai TY, Warrier S. Predicting non-sentinel lymph node metastasis in Australian breast cancer patients: Are the nomograms still useful in the post-Z0011 era? ANZ J Surg. 2019;89(6):712\u20137. https:\/\/doi.org\/10.1111\/ans.15173.","journal-title":"ANZ J Surg"},{"issue":"11","key":"15354_CR42","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1245\/s10434-021-09910-2","volume":"28","author":"TA Moo","year":"2021","unstructured":"Moo TA, Pawloski KR, Flynn J, et al. Is residual nodal disease at axillary dissection associated with tumor subtype in patients with low volume sentinel node metastasis after neoadjuvant chemotherapy? Ann Surg Oncol. 2021;28(11):6044\u201350. https:\/\/doi.org\/10.1245\/s10434-021-09910-2.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"15354_CR43","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/cncr.23481","volume":"112","author":"JS Jeruss","year":"2008","unstructured":"Jeruss JS, Newman LA, Ayers GD, et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008;112(12):2646\u201354. https:\/\/doi.org\/10.1002\/cncr.23481.","journal-title":"Cancer"},{"issue":"10","key":"15354_CR44","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1245\/s10434-018-6578-3","volume":"25","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Boughey JC. Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(10):2867\u201374. https:\/\/doi.org\/10.1245\/s10434-018-6578-3.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"15354_CR45","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/j.acra.2022.03.012","volume":"29","author":"T Zhu","year":"2022","unstructured":"Zhu T, Lin X, Zhang T, et al. A model incorporating axillary tail position on mammography for preoperative prediction of non-sentinel lymph node metastasis in patients with initial cN+ breast cancer after neoadjuvant chemotherapy. Acad Radiol. 2022;29(12):e271\u20138. https:\/\/doi.org\/10.1016\/j.acra.2022.03.012.","journal-title":"Acad Radiol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15354-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T21:04:02Z","timestamp":1720645442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["15354"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15354-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maj-Britt Jensen has received meeting expenses and participated in Advisory Boards for Novartis. Frederikke Munck, Ilse Vejborg, Maria K. Gerlach, Maja V. Maraldo, Niels T. Kroman, Tove H.F. Tvedskov have no conflicts of interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}